(Q36643797)

15 August 2017

Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma (English)

1 reference

15 August 2017

1 reference

Mycobacterium vaccae

1 reference

R Mendes

1

1 reference

15 August 2017

M E R O'Brien

2

1 reference

15 August 2017

A Mitra

3

1 reference

15 August 2017

A Norton

4

1 reference

15 August 2017

R K Gregory

5

1 reference

15 August 2017

A R Padhani

6

1 reference

15 August 2017

K V Bromelow

7

1 reference

15 August 2017

A R Winkley

8

1 reference

15 August 2017

S Ashley

9

1 reference

15 August 2017

I E Smith

10

1 reference

15 August 2017

B E Souberbielle

11

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

86

1 reference

15 August 2017

336-341

1 reference

15 August 2017

3

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

15 August 2017

start time

1 February 2002

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600063

0 references

cites work

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

A highly sensitive whole blood natural killer cell assay

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Chemotherapy in malignant pleural mesothelioma. A review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Continuing increase in mesothelioma mortality in Britain.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Tuberculosis and cancer: parallels in host responses and therapeutic approaches?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375208

Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interkukin-2 in peripheral blood lymphocytes

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600063

Single-cell cytokine profiles in normal humans: comparison of flow cytometric reagents and stimulation protocols

21 January 2018

1 reference

12 December 2020

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

12 December 2020

Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors

1 reference

12 December 2020

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Whole blood assay for assessment of the mixed lymphocyte reaction

1 reference

12 December 2020

A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600063

1 reference

15 August 2017

1 reference

15 August 2017

1 reference